In relation to the data already available, this vaccine has a lower efficacy rate than those of Pfizer / BioNTech or Moderna, which exceed 90%.
The vaccine against covid-19 developed by the British laboratory AstraZeneca and the University of Oxford has an average effectiveness of 70%, according to a statement released this Monday.
These are interim results from large-scale clinical trials developed in the UK and Brazil, says AstraZeneca. In relation to the data already available, this vaccine has a lower average efficacy rate than those reported by Pfizer / BioNTech or Moderna, which exceed 90%.
According to the statement released, no hospitalizations or serious cases of the disease were reported among participants in the tests that received the vaccine and there were 131 cases of covid-19 recorded in the interim analysis.
A dosage regimen showed the vaccine to be 90% effective when it was initially administered in half dose, followed by a full dose at least one month apart.
Read more in Diário de Notícias
This article is available in: Português